摘要
西他列汀是首个二肽基肽酶-4(DPP-4)抑制剂的II型糖尿病治疗药,该药物的制备技术主要经历了三代工艺路线的发展。本文主要综述了西他列汀的制备技术,以及生物催化法应用于西他列汀的合成工艺路线,并对今后西他列汀制备技术的发展方向进行了展望。
Sitagliptin is the first dipeptidyl peptidase-4（DPP-4） inhibitor type II diabetes drug. The development of this drug after the market has gone through three generations of the development process line. In this paper, the preparation technology of sitagliptin and the biocatalytic method applied in the synthesis of sitagliptin were mainly introduced. The future development of sitagliptin preparation technology was also discussed.
作者
章鹏鹏
孟凡婷
牛婷婷
王普
ZHANG Peng-peng MENG Fan-ting NIU Ting-ting WANG Pu(College of Pharmaceutical Science ,Zhejiang University of Technology ,Hangzhou , Zhejiang 310014, China)
出处
《浙江化工》
CAS
2017年第9期15-19,23,共6页
Zhejiang Chemical Industry
基金
浙江省自然科学基金项目(LY16B060010)
国家自然科学基金项目(21676250)资助
